Kimia Farma Earns Revenue Of IDR 4.95 Trillion In Semester I 2023

JAKARTA - A state-owned company (BUMN) in the pharmaceutical sector, PT Kimia Farma Tbk (KAEF) posted revenue of IDR 4.95 trillion in the first semester of 2023, or an increase of 11.78 percent year on year (yoy), from the previous IDR 4.43 trillion in the same period the previous year.

"Chemia Farma's revenue gain, on a consolidated basis until June 2023, is supported by the strong sales of products and improvements in medical and clinical laboratory services," said Kimia Farma President Director David Utama as quoted by Antara, Monday, July 31.

In terms of product categories, David explained that generic drugs contributed revenue of Rp1.07 trillion, or an increase of about 25.26 percent (yoy), from the previous Rp858.96 billion in the same period the previous year.

In addition, sales of ethical products and licenses also increased 13.99 percent (yoy) to Rp1.89 trillion, compared to the previous Rp1.65 trillion in the same period the previous year.

He continued, the company's medical laboratory and clinical services amounted to Rp488.16 billion in the first semester of 2023, or an increase of 16.60 percent (yoy) from the previous Rp418.66 billion in the same period the previous year.

Meanwhile, drug sales Over The Counter (OTC) and cosmetics grew 4.85 percent (yoy) to Rp1.06 trillion in the first semester of 2023, from the previous Rp1.01 trillion.

Meanwhile, the category of medical devices contributed Rp49.02 billion, contracting 14.75 percent (yoy) compared to the previous Rp57.50 billion in the same period the previous year.

The increase in income caused Kimia Farma to be able to record a positive operating profit of IDR 236.29 billion in the first semester of 2023, or inversely proportional to the same period in 2022, where the company still recorded an operating loss of IDR 15.67 billion.

"This positive performance achievement was able to push the bottom line of Kimia Farma by posting a net profit of IDR 19.47 billion throughout the first semester of 2023. When compared to the same period last year, Kimia Farma recorded a net loss of IDR 206.30 billion," said David.

Impressive growth also occurred on the asset side, where the company recorded total assets of IDR 20.60 trillion in the first semester of 2023, or grew around 1.21 percent (yoy) compared to the previous year's period of IDR 20.35 trillion.